Trulieve Cannabis became the first U.S. cannabis company to uplist to the NYSE, improving investor access and liquidity. The company announced a $50 million share repurchase program and reported a profitable first quarter of 2026, generating $42 million in free cash flow. Additionally, the reclassification of medical marijuana to Schedule III removes a significant tax burden, boosting earnings and cash flow. These factors contribute to a positive outlook, with the stock trading at a discounted 5–6x EBITDA valuation and strong regulatory and financial tailwinds supporting a BUY rating.
Jyske Realkredit A/S has published preliminary data regarding early redemptions (prepayments) of its issued bonds, dated August 7, 2026. This disclosure complies with the Capital Markets Act and provides investors with updated information on bond pre...
FLSmidth & Co. A/S continued its share buy-back program initiated on 18 May 2026, repurchasing 61,000 shares between 3 and 7 August 2026 at prices ranging from DKK 487.45 to DKK 511.77 per share. This brings the total shares bought back under the pro...
Jyske Bank has continued its share repurchase program initiated in February 2026, acquiring shares valued at approximately DKK 1.57 billion by early August 2026. The program, which runs until January 29, 2027, allows the bank to buy back shares up to...
Jyske Bank is conducting a share buyback program from February 5, 2026, to January 29, 2027, with a maximum value of DKK 3 billion. As of early August 2026, the bank has repurchased shares worth approximately DKK 1.57 billion at an average price of D...
Quadient has been named among the leading providers in The Forrester Wave™: Accounts Payable Invoice Automation Software, Q2 2026, marking its first inclusion in this key industry evaluation. The recognition highlights Quadient's growing presence and...
